university of groningen

University Medical Center Groningen

University of Groningen

DNA methylation in type 2 diabetes and metabolic health

Walaszczyk, Eliza

DOI:
10.33612/diss.180629925

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Walaszczyk, E. (2021). *DNA methylation in type 2 diabetes and metabolic health*. University of Groningen. https://doi.org/10.33612/diss.180629925

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 05-06-2022

Chapter 5

An epigenome-wide association study identifies multiple DNA methylation markers of exposure to endocrine disruptors

Xueling Lu*, Eliza Fraszczyk*, Thomas P van der Meer, Martijn Faassen, Vincent W Bloks, Ido P Kema, André P. van Beek, Shuang Li, Lude Franke, Harm-Jan Westra, BIOS Consortium, Xijin Xu, Xia Huo, Harold Snieder, Bruce HR Wolffenbuttel, Jana V van Vliet-Ostaptchouk

*Equal contribution

Environ. Int. 144, 106016 (2020); https://doi.org/10.1016/j.envint.2020.106016

Abstract

Background: Exposure to environmental endocrine disrupting chemicals (EDCs) may play an important role in the epidemic of metabolic diseases. Epigenetic alterations may functionally link EDCs with gene expression and metabolic traits.

Objectives: We aimed to evaluate metabolic-related effects of the exposure to endocrine disruptors including five parabens, three bisphenols, and 13 metabolites of nine phthalates as measured in 24-hour urine on epigenome-wide DNA methylation.

Methods: A blood-based epigenome-wide association study was performed in 622 participants from the Lifelines DEEP cohort using Illumina Infinium HumanMethylation450 methylation data and EDC excretions in 24-hour urine. Out of the 21 EDCs, 13 compounds were detected in > 75% of the samples and, together with bisphenol F, were included in these analyses. Furthermore, we explored the putative function of identified methylation markers and their correlations with metabolic traits.

Results: We found 20 differentially methylated cytosine-phosphate-guanines (CpGs) associated with 10 EDCs at suggestive *p-value* < 1x10-6, of which four, associated with MEHP and MEHHP, were genome-wide significant (Bonferroni-corrected *p-value* < 1.19x10-7). Nine out of 20 CpGs were significantly associated with at least one of the tested metabolic traits, such as fasting glucose, glycated hemoglobin, blood lipids, and/or blood pressure. 18 out of 20 EDC-associated CpGs were annotated to genes functionally related to metabolic syndrome, hypertension, obesity, type 2 diabetes, insulin resistance and glycemic traits.

Conclusions: The identified DNA methylation markers for exposure to the most common EDCs provide suggestive mechanism underlying the contributions of EDCs to metabolic health. Follow-up studies are needed to unravel the causality of EDC-induced methylation changes in metabolic alterations.

Introduction

Environmental endocrine disrupting chemicals (EDCs) are considered as obesogens and diabetogens that interfere with energy and macronutrient metabolism, consequently impairing metabolic health[1]. Humans are ubiquitously exposed to non-persistent EDCs, including parabens, bisphenols, and phthalates, due to their widespread applications in miscellaneous consumer products[2]. Parabens are used as anti-microbial preservatives in a wide range of personal care products and food[3]. Bisphenols are one of the highest volume chemicals produced worldwide and used for polycarbonate plastics and epoxy resins, e.g. plastic bottles, food containers, the interior lining of food cans, and thermal receipt papers[4]. Phthalates can be extensively found in soft plastics, pharmaceutical and nutritional supplements, and cosmetics[5]. Accumulating data demonstrated that EDC exposures can promote epigenetic changes by altering methyl donor availability, the activity of histone methyltransferases, and microRNA or noncoding RNA expression[6-9]. Thus, epigenetics may be a crucial mechanism linking environmental chemical exposures to underlying etiology of human metabolic diseases[9].

Given the global epidemic of obesity and type 2 diabetes (T2D) and ubiquitous EDC exposure, evidence is emerging that apart from the unhealthy changes in diets and sedentary lifestyle[10-12], environmental EDC exposure might be an important contributor to explaining the magnitude and dramatic increase in the prevalence of metabolic diseases[13,14]. Numerous population-based and animal studies have established that EDC exposure is associated with insulin resistance, alterations of glucose and lipid metabolism, the development of the metabolic syndrome and T2D[15-17]. Furthermore, DNA methylation, to date the best-characterized epigenetic mechanism, plays an important role in the effects of environmental stimuli on the development of metabolic disorders[18]. Moreover, differential DNA methylation has been identified in genes for T2D and obesity pathogenesis (i.e. *GCK*, *PYY*)[19,20] and genes that impair insulin secretion (i.e. *CACNA2D2*)[21]. However, it remains to be established whether DNA methylation might link exposure to parabens, bisphenols and phthalates to adverse metabolic health.

Therefore, we carried out an epigenome-wide association study (EWAS) to investigate the effects of the most common EDCs, including five parabens, three bisphenols, and 13 metabolites of nine phthalates, on genome-wide DNA methylation patterns in 622 unselected samples from the Lifelines DEEP cohort. In

this study, we address the knowledge gap in understanding the influence of these environmental exposures on DNA methylation in the general population.

Methods

Study population

A total of 622 adults (18-81 years) from the Lifelines DEEP cohort were included in this study based on available epigenome-wide methylation data and 24-hour (24h) urine samples (general characteristics in **Table 1**). Lifelines DEEP is a randomly selected subpopulation of the Lifelines cohort from the north of The Netherlands[22,23]. Blood samples in the fasting state were collected for analysis of laboratory markers and 24h-urine was collected in containers that were accompanied by oral and written instructions[23]. On the day of blood collection, whole blood levels of fasting blood glucose and glycated hemoglobin (HbA1c), and serum levels of blood lipids were measured. A standardized protocol was used to obtain metabolic traits [i.e. fasting glucose, HbA1c, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, diastolic blood pressure, systolic blood pressure] and anthropometric measurements (i.e. waist and hip circumferences, body height and weight), as described in detail elsewhere[23]. All participants provided written informed consent. The study was approved by the Medical Ethical Committee of the University Medical Center Groningen (UMCG), Groningen, The Netherlands.

Chemical analysis

Concentrations of five parabens, three bisphenols, and 13 metabolites of nine different phthalates were measured in 24h-urine samples by offline isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) technology [compound details, abbreviations and limits of detection (LOD) in **Table 2**]. The technical specifications and validity of methods are described elsewhere[24]. For each included compound, exposure levels below LOD were replaced by $LOD/\sqrt{2}$[25]. In the EWAS analysis, we included 14 compounds, 13 of which had $>$ 75% of samples measured above LOD and bisphenol F (BPF) with 52% of samples above LOD. We included BPF because it is a relatively new compound and widely used as a bisphenol A (BPA) substitute[26].

Genome-wide DNA methylation

500 ng of genomic DNA was bisulfite-converted using the EZ DNA Methylation kit (Zymo Research Corp., USA) and hybridized on Illumina Human Methylation 450K BeadChip arrays (Illumina, Inc.) according to the manufacturer's protocols. The original IDAT files were generated by the Illumina iScan BeadChip scanner at the Human Genotyping facility (HugeF) of ErasmusMC, The Netherlands (http://www.glimDNA.org/). The R-package "minfi" was used to perform quality control checks on the probes and samples[27]. We removed samples with probes with a detection *p-value* > 0.01 in more than 1% of probes. Then we performed background correction and probe type normalization using "preprocessQuantile" implemented in the "minfi" package. Sites with single nucleotide polymorphisms (SNPs) were defined by the function "dropLociWithSnps" in the "minfi" package. Next, we dropped probes according to the following criteria: (a) a detection *p-value* > 0.01; (b) bead count < 3 in over 5% of samples; (c) location of a known SNP or SNP at the single base extension site or cytosine-phosphate-guanine (CpG) site; (d) all CpGs on the sex chromosomes; (e) cross-reactive probes (n = 29,233)[28] and multi-mapped probes (n = 33,457)[29]. Ultimately, the probe exclusions resulted in 420,522 high quality CpGs. Prior to linear regression analysis, the methylation dataset was trimmed on: (25th percentile - 3 x IQR) and (75th percentile + 3 x IQR). Such outlying CpG values were set to "missing" and excluded from further analyses. Methylation level (β-value) at each CpG was expressed as the ratio of the methylated intensity over the total intensity, which was used for all subsequent statistical analyses and biological interpretation.

Statistical analyses

Urinary concentrations of the EDCs were measured (ng/mL) and the total excretion per day (ng/24h) was calculated by multiplying the concentration with the 24h-urine volume (mL/24h). Due to non-normal distributions, the excretions of compounds per 24h were presented as median [interquartile range], and Spearman correlation coefficients were used for the relationships among EDCs. To identify associations of differentially methylated probes with urinary concentrations of 14 EDCs, a robust linear regression analysis was performed using the R-package "MASS"[30]. In the regression model, DNA methylation levels (β-values) were used as dependent variables, and log10-transformed EDC excretions in 24 hours (ng/24h) as predictors. To minimize systematic bias of the heterogeneity in blood

cell composition and technical array-related confounders, the regression models were adjusted for age, sex, body mass index (BMI), measured blood cell counts (neutrophils, lymphocytes, monocytes, eosinophils, basophils), array number, and position on the array[31]. Finally, we applied the R-package "QCEWAS" for quality control of EWAS results[32]. In EWAS, we used the Bonferroni-corrected *p-value* $< 1.19 \times 10^{-7}$ as genome-wide significance threshold and *p-value* $< 1 \times 10^{-6}$ as a suggestive threshold.

Correlations between CpG methylation β-values and metabolic traits

To determine the associations of EDC-associated CpG methylation levels with metabolic traits, 200 Spearman correlations were calculated between 10 metabolic traits and the residuals from methylation proportions at 20 CpGs regressed on the covariates mentioned above (i.e. age, sex, BMI, blood cell counts, array number and array position). A false discovery rate (FDR) < 5% was used as the significant threshold. All EWAS and correlational analyses were conducted in R-studio (based on R v3.6.3).

Bioinformatics Characterization of EDC-associated CpGs

We used Illumina's Infinium HumanMethylation450k v1.2 product files (Illumina,. https://support.illumina.com/) and the R-package "FDb.InfiniumMethylation.hg19" to annotate to the nearest gene for each CpG. The bioinformatics characterization of genes annotated to EDC-associated CpG sites (*p-value* $<1 \times 10^{-6}$) from EWAS results were explored.

To clarify the putative function of the suggestive markers and association with any of the metabolic traits (i.e. blood pressure, waist circumference, obesity-related traits, glycemic traits, lipids, diabetes, hypertension), we queried gene names in the GeneCards (the Human Gene Database, https://www.genecards.org/) and the NHGRI-EBI GWAS Catalog (the database of SNP associations in published and peer-reviewed genome-wide association studies, https://www.ebi.ac.uk/gwas/). Moreover, to investigate the relationships of suggestive CpGs with metabolic traits, we searched annotated genes along with metabolic traits (i.e. insulin, glucose, lipids, adiposity, obesity, diabetes and blood pressure) in PubMed.

Expression quantitative trait methylation

To investigate the association between EDC-associated CpGs (at *p-value* $<1\times10^{-5}$) and gene expression, we performed expression quantitative trait methylation (eQTM) analysis in 2,905 whole blood samples from the Biobank-Based Integrative Omics Studies (BIOS) data[33]. Here, we conducted 4,127 CpG-gene combinations by testing the genes within 1Mb of the EDC-associated CpGs. We corrected for multiple testing by calculating an empirical FDR estimate, where we created a null distribution by performing 10 permutations, each time swapping sample labels, and considered FDR $<$ 5% as significant.

Comparative toxicogenomics database

To check the chemical-gene interactions, for each EDC compound, we queried the chemical and corresponding genes identified by eQTM analysis in the integrated Comparative Toxicogenomics Database (CTD, a public resource for toxicogenomic information from the peer-reviewed scientific literature, http://ctdbase.org/). CTD includes manually curated interaction types (i.e. both chemical effects on methylation and gene expression or gene effects on chemical degradation and abundance from population or experimental studies), which we extracted to validate our results.

Table 1. General characteristics of the study population from the Lifelines DEEP cohort

Characteristic	Value (N = 622)
Sex = Male [N (%)]	259 (42%)
Age (years)	46 [36-55]
Weight (kg)	77.0 [67.0-88.0]
Body mass index (kg/m²)	24.7 [22.6-27.5]
Waist circumference (cm)	88.0 [80.0-97.9]
Waist-to-hip ratio *	0.92 (0.1)
Neutrophils (%) *	53.1 (8.2)
Lymphocytes (%)	34.3 [29.8-38.9]
Monocytes (%)	8.2 [7.0-9.7]
Eosinophils (%)	2.7 [1.8-3.9]
Basophils (%)	0.5 [0.3-0.7]
24-hour urine (mL)	1781.5 [1353.0-2288.3]
Fasting glucose (mmol/L)	4.8 [4.6-5.2]
HbA1c (%)	5.5 [5.3-5.7]
Triglycerides (mmol/L)	0.90 [0.67-1.32]
HDL cholesterol (mmol/L)	1.50 [1.20-1.80]
LDL cholesterol (mmol/L)	3.10 [2.50-3.80]
Total cholesterol (mmol/L)	4.95 [4.40-5.70]
Diastolic blood pressure (mm Hg)	70 [64-76]
Systolic blood pressure (mm Hg)	117 [110-128]

Data are given as median [interquartile range] when not normally distributed. * Normally distributed data are expressed as mean (standard deviation). Abbreviations: HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol

Results

Exposure to common EDCs in the Dutch population

Table 2 shows concentrations of all measured compounds in 24h urine voids (ng/mL). Five parabens (MeP, EtP, PrP, n-BuP, BzP), three bisphenols (BPA, BPF, BPS), and 13 metabolites of nine phthalates (MMP, MEP, MiBP, MnBP, MEHP, MnHP, MEHHP, MEOHP, MECPP, MBzP, MiNP, MHiNP, MiDP) were measured in all samples. Of these 21 EDC compounds, MeP, EtP, PrP, n-BuP, BPA, and eight metabolites of the phthalates (MEP, MiBP, MnBP, MEHP, MEHHP, MEOHP, MECPP, MBzP) were detected above the LOD in $>$ 75% of samples; and BPF and MMP in $>$ 50% of samples. Other chemicals (BzP, BPS, MnHP, MiNP, and MiDP) were detected in $<$ 20% of samples, while MHiNP was not detectable at all. All 13 compounds detected in $>$ 75% of samples (plus BPF) were further analyzed.

The correlation plot for the concentrations of these 14 EDC compounds showed high correlations within the same classes of EDCs, i.e., within the four parabens (r_s: 0.34 - 0.71) and within the eight phthalate metabolites (r_s: 0.16 - 0.97), while the correlations between BPA and BPF and across EDC classes were not significant (**Supplementary Figure 1**). The paraben MeP and the phthalate metabolite MEP were excreted in the highest median concentrations followed by MiBP, MnBP, and MECPP. The concentration ranges of the parabens and the phthalate metabolites were wide with maximum levels being 576- (PrP), 307- (n-BuP), 291- (EtP), 161- (MeP), and 139- (MEP), 114- (MnHP), 106- (MBzP) fold higher than the corresponding median concentrations. By comparison, the observed concentration ranges of other analytes were much more narrow [4- (BzP), 27- (BPA), and 87- (BPF), 23- (BPS), 34- (MMP), 20- (MiBP), 21- (MnBP), 19- (MEHP), 20- (MEHHP), 24- (MEOHP), 30- (MECPP), 19- (MEHP), 6- (MiNP), 9- (MiDP) fold higher, respectively].

24h EDC excretions and DNA methylation

The EWAS analysis revealed 21 associations for methylation levels of 20 separate CpG sites (cg06890484 was associated with both MEHHP and MEOHP) with 24h EDC excretions at suggestive *p-value* $< 1x10^{-6}$ (12 for MEHP, one each for PrP, BPA, BPF, MEP, MnBP, MEHHP, MEOHP, MECPP, and MBzP). Four CpGs remained significant at strict Bonferroni-correction (*p-value* $< 1.19x10^{-7}$) and three of these were associated with MEHP (**Table 3**). Details on 204 identified CpGs at *p-value* $< 1x10^{-5}$ from EWAS for a total of 14 compounds are provided in **Supplementary Tables 1-14**, where the effect changes of DNA methylation per unit increase in 24h urinary excretions of log10-transformed EDCs are presented. EWAS-specific quantile-quantile plots with lambdas are shown in **Supplementary Figure 2**. Manhattan plots (**Supplementary Figure 3**) show the location of CpGs for 14 compounds throughout the genome.

CpG methylation levels and metabolic traits

We calculated correlations between the suggestive EDC-associated CpGs and fasting glucose, HbA1c, waist-to-hip-ratio, blood lipids and blood pressure. **Table 4** shows significant correlations of the methylation levels with at least one of the metabolic traits. Nine out of the 20 CpGs were significantly correlated at FDR < 5%, and 11 CpGs at FDR < 10%.

Text box1 in Supplemental Materials describes putative functions of genes that were annotated to the suggestive CpGs in relation to metabolic traits based on the GWAS-catalog. A total of 18 out of 20 genes were assumed to play some part in metabolic health and nine out of 20 genes were reported to be associated with metabolic traits in the GWAS-catalog. Examples included metabolic diseases such as T2D, obesity, and hypertension, as well as continuous traits such as BMI, glycemic traits, and triglycerides.

Association with gene expression

We observed that EDC-associated CpGs (at *p-value* $< 1x10^{-5}$) affect expressions at 46 genes, from 4,127 CpG-gene combinations (FDR < 5%, **Supplementary Table 15**). Only one suggestive CpG (MEHP-associated cg08537847 at *p-value* $< 1x10^{-6}$) was associated with higher gene expression of *PCYOX1L* and *CSF1R* in the eQTM analysis rather than with the annotated gene *CARMN*.

Differential methylation and known EDC-gene interactions

We identified 16 interactions between three chemicals (BPA, MnBP and MEHP) and genes identified in eQTM analysis (**Table 5**). For other compounds, we found no overlap since these EDCs were not present in the CTD. For 11 CpG-gene combinations, the effect directions of interactions reported in the CTD were consistent with our results. For instance, MEPH-associated CpG cg21987356 was positively associated with expressions of *PCYOX1L* and *CSF1R*. Meanwhile, increased expression of *CSF1R* in response to MEHP was reported in the CTD. Moreover, for the rest of five CpG-gene combinations, the effect directions were not uniformly consistent within CTD reports. For example, we observed a positive association between MEHP-associated CpG cg04609694 and *VEGFA* expression, but there were one positive and two negative effects, and one reference does not describe a specific effect degree in the CTD.

Table 2. Concentrations of endocrine disrupting chemicals in 24-hour urine collections (ng/mL)

Compounds		Phthalate metabolites		LOD (ng/mL)	N > LOD (%)	Mean	Min	Q25	Median	Q75	Max	Max / median
Parabens												
Methyl paraben	**MeP**			0.14	622(100)	63.42	0.62	5.73	25.31	76.02	4079.11	161
Ethyl paraben	**EtP**			0.09	609(98)	11.73	0.09	0.56	1.68	7.18	488.21	291
n-Propyl paraben	**PrP**			0.07	577(93)	23.11	0.07	0.70	3.41	21.63	1962.97	576
n-Butyl paraben	**n-BuP**			0.06	531(85)	1.65	0.06	0.10	0.21	0.90	64.48	307
Benzyl paraben	BzP			0.07	31(5)	0.23	0.07	0.12	0.18	0.28	0.71	4
Bisphenols												
Bisphenol A	**BPA**			0.22	588(95)	3.32	0.22	1.08	2.05	3.84	54.39	27
Bisphenol F	**BPF**			0.23	325(52)	1.66	0.23	0.39	0.65	1.44	56.44	87
Bisphenol S	BPS			0.06	57(9)	0.51	0.06	0.1	0.18	0.55	4.06	23
Phthalates												
Di-methyl phthalate	DMP	Mono-methyl phthalate	MMP	0.43	320(51)	1.90	0.43	0.69	1.09	1.89	37.58	34
Di-ethyl phthalate	DEP	Mono-ethyl phthalate	**MEP**	0.35	621(100)	145.28	2.7	20.3	47.58	131.17	6634.73	139
Di-iso-butyl phthalate	DiBP	Mono-iso-butyl phthalate	**MiBP**	0.33	622(100)	29.89	3.71	11.89	19.61	33.01	388.76	20
Di-n-butyl phthalate	DnBP	Mono-n-butyl phthalate	**MnBP**	0.22	622(100)	25.13	2.54	10.61	17.27	28.41	364.48	21
Di-(2-ethyl-hexyl) phthalate	DEHP											

Compounds		Phthalate metabolites		LOD (ng/mL)	N > LOD (%)	Mean	Min	Q25	Median	Q75	Max	Max / median
		Mono-(2-ethylhexyl) phthalate	**MEHP**	0.12	516(83)	3.40	0.16	1.5	2.61	4.06	50.45	19
		Mono-(2-ethyl-5-hydroxyhexyl) phthalate	**MEHHP**	0.11	622(100)	11.64	1.79	6.11	9.10	13.74	182.69	20
		Mono-(2-ethyl-5-oxohexyl) phthalate	**MEOHP**	0.09	622(100)	7.99	0.82	4.08	6.10	9.45	146.13	24
		Mono-(2-ethyl-5-carboxypentyl) phthalate	**MECPP**	0.25	622(100)	12.98	1.74	6.63	10.12	15.44	306.88	30
Di-n-hexyl phthalate	DnHP	Mono-n-hexyl phthalate	MnHP	0.07	123(20)	0.52	0.07	0.10	0.16	0.39	18.22	114
Butylbenzyl phthalate	BBzP	Mono-benzyl phthalate	**MBzP**	0.22	620(100)	11.72	0.28	3.22	5.82	10.76	617	106
Di-iso-nonyl phthalate	DiNP	Mono-iso-nonyl phthalate	MiNP	0.10	5(1)	1.64	0.33	0.60	0.90	1.07	5.31	6
		Mono-hydroxy-iso-nonyl phthalate	MHiNP	0.29	0(0)	NA	NA	NA	NA	NA	NA	NA
Di-iso-decyl phthalate	DiDP	Mono-iso-decyl phthalate	MiDP	0.31	63(10)	0.41	0.31	0.32	0.34	0.36	2.90	9

Abbreviations: LOD, limit of detection; Q25, 25th quartile; Q75, 75th quartile; NA, not available. We performed EWAS for 13 compounds, measured above LOD in >75% of the samples, and BPF, measured in >52% of the samples. These 14 EDCs are indicated in **bold**.

Table 3 Top 20 CpG sites associated with log10-transformed EDC excretions in 24-hour urine at suggestive *p-value* < 1×10^{-6}

EDC	CpG	Nearest Gene	CHR	BP position	Location in gene	Relation to CpG-island	Effect size	Raw *p-value*
PrP	cg04229238	*RB1CC1*	8	53627628	TSS1500	Shore	-0.002	3.50×10^{-7}
BPA	cg08655701	*MRPL4*	19	10363255	Body	Island	-0.008	5.72×10^{-7}
BPF	cg09905416	*MS4A2*	11	59861219	Body		-0.005	9.45×10^{-7}
MEP	cg24882097	*BIRC3*	11	102188439	5'UTR	Island	-0.011	6.32×10^{-7}
MnBP	cg27454300	*TNKS*	8	9414031	1stExon	Island	-0.005	8.83×10^{-7}
MEHP	cg26094004	*PYY*	17	42075116	5'UTR	Shelf	-0.013	$\mathbf{1.41\times10^{-9}}$
	cg07484739	*MIR1246*	2	177356020		Shore	-0.017	$\mathbf{9.77\times10^{-8}}$
	cg20914725	*LOXL3*	2	74776831	Body	Island	0.008	$\mathbf{1.11\times10^{-7}}$
	cg05795313	*ZNF641*	12	48745136	TSS1500	Shore	0.011	2.71×10^{-7}
	cg04533116	*SLC6A19*	5	1169063		Shore	0.015	3.17×10^{-7}
	cg02566391	*IL12RB2*	1	67805528	Body		-0.014	3.40×10^{-7}
	cg21987356	*GCK*	7	44199597	Body		0.004	3.55×10^{-7}
	cg26325335	*CACNA2D2*	3	50402333	Body	Island	0.023	5.04×10^{-7}
	cg18291014	*FAM20C*	7	93658			-0.008	6.56×10^{-7}
	cg08537847	*CARMN*	5	148810203	TSS200		0.012	7.21×10^{-7}
	cg21634100	*FECH*	18	55254527	TSS1500	Shore	0.005	8.94×10^{-7}
	cg01745867	*IER3*	6	30710816	TSS1500	Island	-0.004	9.90×10^{-7}
MEHHP	cg06890484	*PTPRJ*	11	48001940	TSS200	Island	-0.011	$\mathbf{3.74\times10^{-8}}$
MEOHP	cg06890484	*PTPRJ*	11	48001940	TSS200	Island	-0.01	1.44×10^{-7}
MECPP	cg05100540	*RPS12*	6	133135557	TSS200	Island	-0.005	6.47×10^{-7}
MBzP	cg26759551	*FBP1*	9	97401509	1stExon	Island	0.005	7.50×10^{-7}

> 75 % of the samples detected above LOD (limits of detection) were used in the robust linear regression models, which were adjusted for covariates: age, sex, body mass index, array number and position on array, measured cell counts (neutrophils, lymphocytes, monocytes, eosinophils, basophils). The numbers of CpGs associated with log10-transformed EDCs are four at Bonferroni-correction < 1.19×10^{-7} (in **bold**) and 20 at *p-value* < 1×10^{-6}.
Abbreviations: PrP, n-Propyl paraben; BPA, Bisphenol A; BPF, Bisphenol F; MEP, Mono-ethyl phthalate; MnBP, Mono-n-butyl phthalate; MEHP, Mono-(2-ethylhexyl) phthalate; MEHHP, Mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, Mono-(2-ethyl-5-oxohexyl) phthalate; MECPP, Mono-(2-ethyl-5-carboxypentyl) phthalate; MBzP, Mono-benzyl phthalate.

Table 4. Spearman correlations between methylation levels of 20 CpGs and metabolic traits

EDC	CpG	Nearest Gene	Metabolic trait (correlation coefficient)			
PrP	cg04229238	*RB1CC1*	\			
BPA	cg08655701	*MRPL4*	DBP (0.09)			
BPF	cg09905416	*MS4A2*	\			
MEP	cg24882097	*BIRC3*	\			
MnBP	cg27454300	*TNKS*	\			
MEHP	cg26094004	*PYY*	**Triglycerides (0.10)**	**HDL (-0.10)**		
	cg07484739	*MIR1246*	Triglycerides (0.09)	**DBP (0.15)**	**SBP (0.15)**	**WHR (0.11)**
	cg20914725	*LOXL3*	**HbA1c (0.11)**	**Cho (0.10)**		
	cg05795313	*ZNF641*	**HDL (0.13)**			
	cg04533116	*SLC6A19*	**HDL (0.12)**	Triglycerides (-0.09)	**DBP (-0.10)**	
	cg02566391	*IL12RB2*	**HbA1c (-0.10)**	HDL (-0.09)	SBP (0.09)	**DBP (0.11)**
	cg21987356	*GCK*	\			
	cg26325335	*CACNA2D2*	**Glucose (0.11)**			
	cg18291014	*FAM20C*	**HbA1c (-0.11)**	**Triglycerides (0.10)**	**HDL (-0.16)**	
	cg08537847	*CARMN*	HbA1c (0.09)	HDL (0.09)	DBP (-0.09)	
	cg21634100	*FECH*	\			
	cg01745867	*IER3*	\			
MEHHP	cg06890484	*PTPRJ*	\			
MEOHP	cg06890484	*PTPRJ*	\			
MECPP	cg05100540	*RPS12*	\			
MBzP	cg26759551	*FBP1*	**Glucose (-0.10)**	**Triglycerides (-0.10)**	HDL (0.09)	

Spearman correlations were adjusted for age, sex, body mass index, cell counts, array number and position on array. **Bold** traits: significant at FDR < 5%. Other traits: significant at FDR < 10%.

Abbreviations: FDR, false discovery rate; PrP, n-Propyl paraben; BPA, Bisphenol A; BPF, Bisphenol F; MEP, Mono-ethyl phthalate; MnBP, Mono-n-butyl phthalate; MEHP, Mono-(2-ethylhexyl) phthalate; MEHHP, Mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, Mono-(2-ethyl-5-oxohexyl) phthalate; MECPP, Mono-(2-ethyl-5-carboxypentyl) phthalate; MBzP, Mono-benzyl phthalate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; Cho, cholesterol; WHR, waist-to-hip ratio; DBP, diastolic blood pressure; SBP, systolic blood pressure.

Table 5. The eQTM-identified genes known to interact with EDCs from the comparative toxicogenomics database (CTD)

EDC	CpG	eQTM gene	Effect size of CpG on gene expression	FDR	Gene-chemical interaction from the CTD
BPA	cg16711332	*PLEKHG5*	-11.16	< 0.001	**Expression (-); Methylation (-)**
MnBP	cg12427444	*HSPA1B*	-4.18	0.011	Expression (+4); Expression (affect 1)
MEHP	cg08537847*	*CSF1R*	3.64	0.036	**Expression (+)**
	cg08537847*	*PCYOX1L*	4.79	< 0.001	NA
	cg05006384	*DICER1*	-4.41	0.004	**Expression (-); Expression (affect 3)**
	cg23357708	*RPS28*	-6.16	< 0.001	**Expression (-3)**
	cg23357708	*SNAPC2*	-5.42	< 0.001	**Expression (-2)**
	cg02696067	*VARS2*	3.80	0.027	**Expression (+)**
	cg03065503	*NSG1*	4.04	0.010	Expression (-); Methylation (affect 1)
	cg22491680	*HAL*	-5.19	< 0.001	Expression (affect 2)
	cg02296171	*PTH2R*	-14.10	< 0.001	**Expression (-)**
	cg25143871	*FBXO21*	3.88	0.026	**Expression (+)**
	cg07043361	*TPCN1*	3.63	0.035	Expression (affect)
	cg10502324	*NAP1L1*	-3.83	0.026	**Expression (-2); Expression (affect 2)**
	cg03331229	*MMP1*	-4.82	< 0.001	**Expression (-2); Expression (affect)**
	cg04609694	*NFKBIE*	4.97	< 0.001	**Expression (+2)**
☐	cg04609694	*VEGFA*	4.69	< 0.001	Expression (-2); Expression (affect); Expression (+)

*CpG site survived at *p-value* $< 1x10^{-6}$. The chemical-gene interaction queries were performed in the CTD database (http://ctdbase.org) for each compound together with the corresponding gene identified in Biobank-Based Integrative Omics Studies (BIOS) data using expression quantitative trait methylation (eQTMs) analysis. **Bold** interactions indicate that the effect of CpG on gene expression are directionally consistent with eQTM results. +/-, positive or negative effects; affect, the reference does not describe a more specific degree; e.g. expression (+2) means that 3 reports have increased gene expression in response to the corresponding chemical. **Abbreviations**: EDC, environmental disrupting chemical; FDR, false discovery rate; BPA, bisphenol A; MnBP, Mono-n-butyl phthalate; MEHP, Mono-(2-ethylhexyl) phthalate; NA, not available.

Discussion

We assessed genome-wide DNA methylation patterns associated with exposure to 14 common non-persistent EDCs (four parabens, two bisphenols and eight phthalate metabolites) in the general Dutch population. EWAS analysis identified 20 CpG sites at suggestive *p-value* $< 1\times10^{-6}$ associated with 24h-urine concentrations of 10 EDCs; four CpGs survived the Bonferroni-correction. Furthermore, 11 out of the 20 EDC-associated CpG sites were significantly correlated with multiple metabolic traits, which may indicate that the differential methylation markers functionally link EDC exposure to metabolic homeostasis.

We identified that 18 out of the 20 genes annotated to suggestive CpGs were reported to be involved in metabolic health. Three out of four genome-wide significant methylation markers: cg26094004 in *PYY*, cg07484739 in *miR1246*, and cg20914725 in *LOXL3*, showed significant associations with MEHP and metabolic traits including HbA1c, triglycerides, HDL-cholesterol, total cholesterol, blood pressure, and waist-to-hip ratio. *PYY* encodes a member of the neuropeptide Y family of peptides. These peptides regulate pancreatic secretion, glucose metabolism and energy homeostasis, suggesting a close association with T2D and obesity[19,34]. Mature miR1246 is incorporated into an RNA-induced silencing complex (RISC), which in human islets exerts an essential effect on islet function and T2D pathogenesis[35]. *LOXL3* interacts with STAT3 signaling pathway, which participates in the pathogenesis of inflammation and insulin resistance[36,37]. The fourth methylation marker, cg06890484 in *PTPRJ*, was associated with both MEHHP and MEOHP, which may be explained by the high correlation between the two compounds. None of the metabolic traits were significantly associated with cg06890484. However, *PTPRJ* has been identified in a GWAS on hypertension[38]. *PTPRJ* acts as a negative regulator of the insulin signaling pathway and suppresses insulin sensitivity in a mouse model[39]. In our analysis of 14 EDCs, MEHP showed to have the largest effect on methylation in terms of the identified number of CpGs mapped to the different genes, which was also reflected in its relatively large statistical inflation of the association *p-value* (lambda = 1.357; **Supplementary Figures 2 and 3**), indicating high potency of MEHP to promote epigenetic changes. These observations are consistent with previous findings showing that MEHP has larger metabolic impact than other phthalate metabolites[40]. Taken together, our EDC data and in particular the MEHP results suggest that disruption of DNA methylation might underlie the association between endocrine disruptors and metabolic alterations.

Additionally, EDC-associated CpGs likely contributed to altered gene expressions. Among the differential methylation CpGs were linked 16 genes known from experimental and toxicological studies to interact with EDCs, as reported in the CTD. In eQTM analysis, one CpG was significantly associated with expression of two genes (i.e. cg08537847 with higher *PCYOX1L* and *CSF1R* expression). *PCYOX1L*, known as prenylcysteine oxidase 1 like, is involved in prenylcysteine oxidase activity and oxidoreductase activity, which is important in protein metabolism and metabolic homeostasis. *CSF1R* encodes colony stimulating factor 1 receptor, and its increased expression was reportedly induced by exposure to di(2-ethylhexyl) phthalate[41]. Moreover, *CSF1R* plays an important role in inflammation and mediates the pathological process of adverse metabolic effects[42]. Collectively, evidence above indicate that the EDC-associated CpGs could be suggestive markers for assessing the potential biological effects of EDCs on metabolic health.

Strengths and limitations

One of the strengths of our study is the use of EDC excretions in 24h urine. As reported previously, 24h-urine collections accurately reflect daily environmental exposures[43,44]. The analytical methodology has been validated in our technical report[24]. Secondly, we adjusted EWAS analysis for measured blood cell counts and possible batch effects (array number and the position on array). The EDC effects on DNA methylation in our study are unlikely to represent the methylation shifts due to cell composition or technical bias. Finally, recent data indicate that methylation profiles in other tissues can be (partly) mirrored in blood[45], supporting blood as a good proxy tissue to capture DNA methylation patterns.

Some limitations must be taken into account. Firstly, the cross-sectional design of our study is not optimal for estimating the causal effects of EDC exposures on epigenetic modifications. We acknowledge that mediation analysis, or even better Mendelian randomization analysis, would help explore possible casual relationships. However, we decided not to include such analyses in the current paper as the modest effect sizes of the Spearman correlations in combination with our relatively modest sample size of n = 622 indicate we would have limited power to successfully perform such analyses[46]. Further analyses in prospective populations are required to establish the dynamic of the epigenetic changes in response to EDC exposures.

Secondly, some previous studies have reported EWAS results with some of the EDCs in this study, e.g. for BPA and phthalates[47,48]. However, we were unable to replicate our findings in independent samples due to the fact that the present study, to the best of our knowledge, is the first EWAS simultaneously investigating DNA methylation patterns associated with multiple common non-persistent EDCs. Moreover, variations between the populations, the collection of urine samples and the analytical methodology, may explain the differences. Nevertheless, we used different methods to support our findings (i.e. toxicogenomic-based approach to check known chemical-gene interactions and the GWAS-catalog) and also compared the results with the existing literature. Although the eQTM analysis did not reveal the effects of EDC-associated methylation at most of suggestive CpGs on the expression levels of the annotated genes, our findings were somewhat supported by the data and observations reported previously in both epidemiological and functional studies in the CTD database. We acknowledge though that, e.g., verification of our results in independent samples and functional studies would have been preferred to validate our results.

Thirdly, we recognize the potential of identification of false positive (while still unreplicated) results and the single measurement of EDC levels which can vary from day to day. We acknowledged that there might be some unexpected confounders because DNA methylation and EDC levels were measured in different tissues. However, blood is known to be a good proxy tissue reflecting the epigenetic profiles in other tissues[45]. Also, the analysis was adjusted for the relevant covariates. However, several of our findings were supported by data and observations reported previously in both epidemiological and experimental studies. We cannot exclude that DNA methylation are linked to the EDC excretions.

Lastly, we did not explore the combined biological effects of all measured EDCs in one model because of the potential collinearity from the close correlations between compounds. However, with one exception the top CpG sites were different for each compound, perhaps indicating that their specific methylation target sites may differ.

Conclusions

To conclude, our findings suggest that differential methylation markers associated with metabolic traits may partly be attributable to non-persistent EDC exposures (PrP, BPA, BPF, MEP, MnBP, MEHP, MEHHP, MEOHP, MECPP, MBzP). Replication

samples and longitudinal studies are necessary to further examine the causal role of EDC-affected DNA methylation in the onset of metabolic diseases.

Acknowledgments

The authors wish to acknowledge all participants of the Lifelines Cohort. We thank Hanne Frederiksen, Copenhagen University Hospital, for critical comments on the manuscript. We thank the Genome Analysis Facility of the University of Groningen, University Medical Center Groningen, for performing the Illumina 450K methylation array experiments.

Funding

This work was supported by a Diabetes Funds Junior Fellowship from the Dutch Diabetes Research Foundation (to JVvVO, project no. 2013.81.1673), and by the National Consortium for Healthy Ageing (NCHA) (NCHA NGI Grant 050-060-810).

Author contributions

XL performed the analysis, interpreted data and wrote the manuscript. EF performed the analysis, interpreted data and contributed to writing the manuscript. TPvdM acquired the data. MF performed the measurements. VWB performed the analysis and contributed to interpretation of the data and analyses. APvB acquired data and/or provided study materials. IPK coordinated the measurements. LF acquired data. HJW contributed to interpretation of the analyses results. SL performed the analysis. XX and XH critically revised the article. HS contributed to interpretation of the analyses and critically revised the article for important intellectual content. BHRW acquired data and/or provided study materials. JVvVO conceived, designed and implemented the study, and involved in data acquisition, interpreted data and contributed to writing the manuscript. All authors reviewed and approved the final manuscript.

Competing interests

The authors declare no competing financial and/or non-financial interests in relation to the work described.

References

1. Kassotis, C. D. *et al.* Endocrine-Mediated Mechanisms of Metabolic Disruption and New Approaches to Examine the Public Health Threat. *Front. Endocrinol. (Lausanne)* 10, 39 (2019).
2. Li, D. *et al.* Health risks of chemicals in consumer products: A review. *Environ Int* 123, 580-587 (2019).
3. Błędzka, D. *et al.* Parabens. From environmental studies to human health. *Environ Int* 67, 27-42 (2014).
4. Andra, S. S. *et al.* Biomonitoring of human exposures to chlorinated derivatives and structural analogs of bisphenol A. *Environ Int* 85, 352-379 (2015).
5. Benjamin, S. *et al.* Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. *J. Hazard. Mater.* 340, 360-383 (2017).
6. Bowman, A. *et al.* Phthalate Exposures, DNA Methylation and Adiposity in Mexican Children Through Adolescence. *Front Public Health* 7, 162 (2019).
7. Martinez, R. M. *et al.* Urinary concentrations of phenols and phthalate metabolites reflect extracellular vesicle microRNA expression in follicular fluid. *Environ Int* 123, 20-28 (2019).
8. Walker, C. L. Minireview: Epigenomic Plasticity and Vulnerability to EDC Exposures. *Mol. Endocrinol.* 30, 848-855 (2016).
9. Singh, S. *et al.* Epigenetic effects of environmental chemicals bisphenol A and phthalates. *Int. J. Mol. Sci.* 13, 10143-10153 (2012).
10. Unnikrishnan, R. *et al.* Type 2 Diabetes: Demystifying the Global Epidemic. *Diabetes* 66, 1432-1442 (2017).
11. Zobel, E. H. *et al.* Global Changes in Food Supply and the Obesity Epidemic. *Curr Obes Rep* 5, 449-455 (2016).
12. Cho, N. H. *et al.* IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res. Clin. Pract.* 138, 271-281 (2018).
13. Le Magueresse-Battistoni, B. *et al.* Endocrine disrupting chemicals in mixture and obesity, diabetes and related metabolic disorders. *World J. Biol. Chem.* 8, 108-119 (2017).
14. Rancière, F. *et al.* Exposure to Bisphenol A and Bisphenol S and Incident Type 2 Diabetes: A Case-Cohort Study in the French Cohort D.E.S.I.R. *Environ Health Perspect* 127, 107013 (2019).
15. Regnault, C. *et al.* Unexpected metabolic disorders induced by endocrine disruptors in Xenopus tropicalis provide new lead for understanding amphibian decline. *Proc Natl Acad Sci U S A* 115, E4416-e4425 (2018).
16. Thayer, K. A. *et al.* Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. *Environ Health Perspect* 120, 779-789 (2012).
17. Sun, Q. *et al.* Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2 diabetes: a prospective investigation in the Nurses' Health Study (NHS) and NHSII cohorts. *Environ Health Perspect* 122, 616-623 (2014).
18. Rosen, E. D. *et al.* Epigenetics and Epigenomics: Implications for Diabetes and Obesity. *Diabetes* 67, 1923-1931 (2018).
19. Guida, C. *et al.* PYY plays a key role in the resolution of diabetes following bariatric surgery in humans. *EBioMedicine* 40, 67-76 (2019).
20. Wang, F. *et al.* Retinol binding protein 4 mediates MEHP-induced glucometabolic abnormalities in HepG2 cells. *Toxicology* 424, 152236 (2019).

21. Cromer, M. K. *et al.* Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas. *Proc Natl Acad Sci U S A* 112, 4062-4067 (2015).
22. Tigchelaar, E. F. *et al.* Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. *BMJ Open* 5, e006772 (2015).
23. Scholtens, S. *et al.* Cohort Profile: LifeLines, a three-generation cohort study and biobank. *Int. J. Epidemiol.* 44, 1172-1180 (2015).
24. van der Meer, T. P. *et al.* Development and Interlaboratory Validation of Two Fast UPLC-MS-MS Methods Determining Urinary Bisphenols, Parabens and Phthalates. *J. Anal. Toxicol.* 43, 452-464 (2019).
25. Frederiksen, H. *et al.* Urinary excretion of phthalate metabolites, phenols and parabens in rural and urban Danish mother-child pairs. *Int. J. Hyg. Environ. Health* 216, 772-783 (2013).
26. Rochester, J. R. *et al.* Bisphenol S and F: A Systematic Review and Comparison of the Hormonal Activity of Bisphenol A Substitutes. *Environ Health Perspect* 123, 643-650 (2015).
27. Maksimovic, J. *et al.* A cross-package Bioconductor workflow for analysing methylation array data. *F1000Res* 5, 1281 (2016).
28. Chen, Y. A. *et al.* Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics* 8, 203-209 (2013).
29. Benton, M. C. *et al.* An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. *Genome Biol* 16, 8 (2015).
30. Ripley, B. *et al.* Package 'MASS'. (2013); Available from:https://cran.rproject.org/web/packages/MASS/MASS.pdf.
31. Shiwa, Y. *et al.* Adjustment of Cell-Type Composition Minimizes Systematic Bias in Blood DNA Methylation Profiles Derived by DNA Collection Protocols. *PLoS One* 11, e0147519 (2016).
32. Van der Most, P. J. *et al.* QCEWAS: automated quality control of results of epigenome-wide association studies. *Bioinformatics* 33, 1243-1245 (2017).
33. Bonder, M. J. *et al.* Disease variants alter transcription factor levels and methylation of their binding sites. *Nat. Genet.* 49, 131-138 (2017).
34. Wu, Y. *et al.* The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis. *Curr Protein Pept Sci* 20, 750-758 (2019).
35. Kameswaran, V. *et al.* Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. *Cell Metab.* 19, 135-145 (2014).
36. Heo, Y. J. *et al.* Visfatin Induces Inflammation and Insulin Resistance via the NF-κB and STAT3 Signaling Pathways in Hepatocytes. *J Diabetes Res* 2019, 4021623 (2019).
37. Laurentino, T. S. *et al.* LOXL3 Function Beyond Amino Oxidase and Role in Pathologies, Including Cancer. *Int. J. Mol. Sci.* 20 (2019).
38. German, C. A. *et al.* Ordered multinomial regression for genetic association analysis of ordinal phenotypes at Biobank scale. *Genet. Epidemiol.* 44, 248-260 (2020).
39. Krüger, J. *et al.* Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice. *Mol Metab* 4, 325-336 (2015).

40. Piecha, R. *et al.* Urine Levels of Phthalate Metabolites and Bisphenol A in Relation to Main Metabolic Syndrome Components: Dyslipidemia, Hypertension and Type 2 Diabetes. A Pilot Study. *Cent Eur J Public Health* 24, 297-301 (2016).
41. Fang, H. *et al.* Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPARγ/PTEN/AKT pathway in differentiated human embryonic stem cells. *Food Chem. Toxicol.* 131, 110552 (2019).
42. Theurich, S. *et al.* IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis. *Cell Metab.* 26, 171-184. e176 (2017).
43. Sun, Q. *et al.* Reproducibility of urinary biomarkers in multiple 24-h urine samples. *Am. J. Clin. Nutr.* 105, 159-168 (2017).
44. Calafat, A. M. *et al.* Optimal Exposure Biomarkers for Nonpersistent Chemicals in Environmental Epidemiology. *Environ Health Perspect* 123, A166-168 (2015).
45. Wahl, S. *et al.* Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature* 541, 81-86 (2017).
46. Relton, C. L. *et al.* Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. *PLoS Med.* 7, e1000356 (2010).
47. Miura, R. *et al.* An epigenome-wide analysis of cord blood DNA methylation reveals sex-specific effect of exposure to bisphenol A. *Sci. Rep.* 9, 12369 (2019).
48. Grindler, N. M. *et al.* Exposure to Phthalate, an Endocrine Disrupting Chemical, Alters the First Trimester Placental Methylome and Transcriptome in Women. *Sci. Rep.* 8, 6086 (2018).